Introduction:
FUJIFILM Corporation plans to invest US$83 million dollars to expand microbial production capacity of FUJIFILM Diosynth Biotechnologies (FDB).
Features:
The new site will be located at United Kingdom and scheduled to begin its operations after 2022.
The building consists of new production line fully equipped with 2 X 2000L fermenters and a modular purification suite allowing FDB to meet the growing demand of microbial expressed therapies and also to develop antibodies and gene therapies.
The facility is not only meant to upgrade high volume production, also triple the FDB’s current capacity of microbial production at the United Kingdom site.
With this expansion, Fujifilm desired to achieve sales of 100 billion yen in the Bio CDMO business by ensuring the commitment of offering different types of therapies named recombinant proteins, antibodies, hormones, viral vectors and providing vaccines for customers with high quality products to grant unmet medical needs in healthcare sector.
The company expects that the increased microbial production capacitywill be ready after 2022.
Specifications:
| Name | FUJIFILM Diosynth Biotechnologies (FDB) |
| Type | Expansion |
| Budget | US$83m |
| Year | 2022 |
